Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening. on.wsj.com/3QVQm4V
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.
on.wsj.com
July 2, 2026 at 5:52 AM
Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening. on.wsj.com/3QVQm4V
For lung cancer driven by KRAS G12C mutations, a new drug, divarasib, just outperformed existing treatments in a Phase 3 trial, significantly improving patient survival. It’s a meaningful step for how we approach targeted therapies.
Roche's Divarasib Demonstrates Superiority Over Approved KRAS G12C Inhibitors in Phase 3 Lung Cancer
Roche has announced positive top-line results from its Phase 3 KRASCENDO-1 study, showing that its investigational drug, divarasib, significantly improved both progression-free survival and overall su
oncodaily.com
July 7, 2026 at 2:01 PM
For lung cancer driven by KRAS G12C mutations, a new drug, divarasib, just outperformed existing treatments in a Phase 3 trial, significantly improving patient survival. It’s a meaningful step for how we approach targeted therapies.
Roche Sees More Potential in Divarasib, Leans Into Autonomous AI Labs
Roche Sees More Potential in Divarasib, Leans Into Autonomous AI Labs
The Swiss drugmaker also revealed at its annual Pharma Day that it has halted a CDK4 program.
ebx.sh
September 29, 2026 at 3:32 AM
Roche Sees More Potential in Divarasib, Leans Into Autonomous AI Labs
Strong representation from our Experimental Cancer Medicines Team (ECMT) at The Christie, led by Dr Matthew Krebs at #ESMO25.
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
October 17, 2025 at 3:24 PM
Strong representation from our Experimental Cancer Medicines Team (ECMT) at The Christie, led by Dr Matthew Krebs at #ESMO25.
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
People with previously treated KRAS G12C lung cancer may have a stronger option ahead.
July 9, 2026 at 12:09 PM
People with previously treated KRAS G12C lung cancer may have a stronger option ahead.
¿Qué sabes sobre el #Divarasib para el tratamiento de cáncer de pulmón?
Si te perdiste el evento en vivo, te invitamos a estar atento a nuestras redes sociales, donde estaremos compartiendo la grabación del evento completo.
#cáncerdepulmón #terapiasdirigidas #Divarasib #KRAS #G12Ci
Si te perdiste el evento en vivo, te invitamos a estar atento a nuestras redes sociales, donde estaremos compartiendo la grabación del evento completo.
#cáncerdepulmón #terapiasdirigidas #Divarasib #KRAS #G12Ci
August 9, 2025 at 4:37 PM
¿Qué sabes sobre el #Divarasib para el tratamiento de cáncer de pulmón?
Si te perdiste el evento en vivo, te invitamos a estar atento a nuestras redes sociales, donde estaremos compartiendo la grabación del evento completo.
#cáncerdepulmón #terapiasdirigidas #Divarasib #KRAS #G12Ci
Si te perdiste el evento en vivo, te invitamos a estar atento a nuestras redes sociales, donde estaremos compartiendo la grabación del evento completo.
#cáncerdepulmón #terapiasdirigidas #Divarasib #KRAS #G12Ci
Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC @columbiacancer.bsky.social #oncology #NSCLC
www.onclive.com/view/divaras...
www.onclive.com/view/divaras...
Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
March 24, 2025 at 6:03 PM
Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC @columbiacancer.bsky.social #oncology #NSCLC
www.onclive.com/view/divaras...
www.onclive.com/view/divaras...
Stephan Bachmann as representative of @Roche presents the #Sandmeyer_prize 2025 lecture «A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib» @swisschemistry.bsky.social #fs25
April 4, 2025 at 8:01 AM
Stephan Bachmann as representative of @Roche presents the #Sandmeyer_prize 2025 lecture «A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib» @swisschemistry.bsky.social #fs25
Divarasib adlı yeni bir hap, ilaç, tablet tedavisinin KRAS G12C mutasyonuyla ilişkili zorlu bir bağırsak kanseri türünün (kolorektal kanser) tedavisinde oldukça etkili olduğu gösterilmiş. Faz 1 www.nature.com/articles/s41...
December 5, 2023 at 8:27 PM
Divarasib adlı yeni bir hap, ilaç, tablet tedavisinin KRAS G12C mutasyonuyla ilişkili zorlu bir bağırsak kanseri türünün (kolorektal kanser) tedavisinde oldukça etkili olduğu gösterilmiş. Faz 1 www.nature.com/articles/s41...
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C https://covalentmodifiers.blogspot.com/2026/03/discovery-and-characterization-of.html
March 4, 2026 at 7:00 PM
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C https://covalentmodifiers.blogspot.com/2026/03/discovery-and-characterization-of.html
Roche's divarasib beat Amgen's and Bristol Myers' drugs in a head-to-head Phase 3 lung cancer trial, improving both survival measures.
Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study
Roche’s lung cancer next-generation KRAS G12C inhibitor drug candidate divarasib has beaten rivals in a head-to-head trial.
endpoints.news
July 2, 2026 at 2:11 PM
Roche's divarasib beat Amgen's and Bristol Myers' drugs in a head-to-head Phase 3 lung cancer trial, improving both survival measures.
The structure of KRASG12C bound to divarasib highlights features of potent switch-II pocket engagement https://covalentmodifiers.blogspot.com/2025/07/the-structure-of-krasg12c-bound-to.html
July 23, 2025 at 10:00 PM
The structure of KRASG12C bound to divarasib highlights features of potent switch-II pocket engagement https://covalentmodifiers.blogspot.com/2025/07/the-structure-of-krasg12c-bound-to.html
💥 For years, the KRAS market belonged to two competitors.
Roche may have just changed the competitive landscape.
Phase 3 results showed divarasib improved OS and PFS vs. both approved therapies in KRAS G12C NSCLC.
👉 Follow @sbokhiria.bsky.social for more insights like this!
#KRAS #KIRIA
Roche may have just changed the competitive landscape.
Phase 3 results showed divarasib improved OS and PFS vs. both approved therapies in KRAS G12C NSCLC.
👉 Follow @sbokhiria.bsky.social for more insights like this!
#KRAS #KIRIA
July 6, 2026 at 3:02 PM
💥 For years, the KRAS market belonged to two competitors.
Roche may have just changed the competitive landscape.
Phase 3 results showed divarasib improved OS and PFS vs. both approved therapies in KRAS G12C NSCLC.
👉 Follow @sbokhiria.bsky.social for more insights like this!
#KRAS #KIRIA
Roche may have just changed the competitive landscape.
Phase 3 results showed divarasib improved OS and PFS vs. both approved therapies in KRAS G12C NSCLC.
👉 Follow @sbokhiria.bsky.social for more insights like this!
#KRAS #KIRIA
The OncoAlert #WCLC26 Top 10 Deep Dive!
OA04.04 — Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data
⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! Not Speaker Slides
OA04.04 — Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data
⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! Not Speaker Slides
September 3, 2026 at 12:01 PM
A new study on divarasib, a KRAS G12C inhibitor, reveals it stabilizes RBM39 protein and blocks its degradation by aryl-sulfonamide degraders.
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
August 23, 2026 at 8:27 PM
A new study on divarasib, a KRAS G12C inhibitor, reveals it stabilizes RBM39 protein and blocks its degradation by aryl-sulfonamide degraders.
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
Researchers have identified that divarasib, a KRAS G12C inhibitor used for treating non-small cell lung cancer, stabilizes RBM39, an essential splicing factor.
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
August 23, 2026 at 12:23 AM
Researchers have identified that divarasib, a KRAS G12C inhibitor used for treating non-small cell lung cancer, stabilizes RBM39, an essential splicing factor.
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
🔗 Source: https://doi.org/10.64898/2026.08.16.745134
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
August 22, 2026 at 3:06 AM
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
August 22, 2026 at 3:06 AM
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
August 20, 2026 at 8:01 PM
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
August 20, 2026 at 8:01 PM
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders https://www.biorxiv.org/content/10.64898/2026.08.16.745134v1
Zurich analyst: I watch $RHHBY - Roche via ROG.SW; KRAS win fuels EU pricing ascent. https://medcitynews.com/2026/07/roche-non-small-cell-lung-cancer-krasg12c-ras-divarasib-rhhby/
August 7, 2026 at 2:06 PM
Zurich analyst: I watch $RHHBY - Roche via ROG.SW; KRAS win fuels EU pricing ascent. https://medcitynews.com/2026/07/roche-non-small-cell-lung-cancer-krasg12c-ras-divarasib-rhhby/
Roche has reported positive Phase III results for divarasib, with the targeted therapy outperforming current KRAS G12C treatments in advanced lung cancer.
www.roche.com/media/releas...
#LungCancer #TargetedTherapy #TCSC
www.roche.com/media/releas...
#LungCancer #TargetedTherapy #TCSC
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements i...
www.roche.com
July 6, 2026 at 8:43 AM
Roche has reported positive Phase III results for divarasib, with the targeted therapy outperforming current KRAS G12C treatments in advanced lung cancer.
www.roche.com/media/releas...
#LungCancer #TargetedTherapy #TCSC
www.roche.com/media/releas...
#LungCancer #TargetedTherapy #TCSC
News from Industry/ Krascendo 1 Update in #NSCLC #LungCancer
Source Genetech
www.gene.com/media/press-...
Genentech announced positive Phase III Krascendo 1 results showing that the investigational KRAS G12C inhibitor divarasib significantly improved progression-free and overall survival
Source Genetech
www.gene.com/media/press-...
Genentech announced positive Phase III Krascendo 1 results showing that the investigational KRAS G12C inhibitor divarasib significantly improved progression-free and overall survival
July 3, 2026 at 3:35 PM
News from Industry/ Krascendo 1 Update in #NSCLC #LungCancer
Source Genetech
www.gene.com/media/press-...
Genentech announced positive Phase III Krascendo 1 results showing that the investigational KRAS G12C inhibitor divarasib significantly improved progression-free and overall survival
Source Genetech
www.gene.com/media/press-...
Genentech announced positive Phase III Krascendo 1 results showing that the investigational KRAS G12C inhibitor divarasib significantly improved progression-free and overall survival